You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
|
|---|---|
| Published in |
Journal of Translational Medicine, November 2019
|
| DOI | 10.1186/s12967-019-02132-x |
| Pubmed ID | |
| Authors |
Alessio Cortellini, Maria G. Vitale, Federica De Galitiis, Francesca R. Di Pietro, Rossana Berardi, Mariangela Torniai, Michele De Tursi, Antonino Grassadonia, Pietro Di Marino, Daniele Santini, Tea Zeppola, Cecilia Anesi, Alain Gelibter, Mario Alberto Occhipinti, Andrea Botticelli, Paolo Marchetti, Francesca Rastelli, Federica Pergolesi, Marianna Tudini, Rosa Rita Silva, Domenico Mallardo, Vito Vanella, Corrado Ficorella, Giampiero Porzio, Paolo A. Ascierto |
| Abstract |
Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial. The aim of this retrospective multicenter study was to evaluate the correlations between "early ir-fatigue", "delayed ir-fatigue", and clinical outcomes in cancer patients receiving PD-1/PD-L1 inhibitors in clinical practice. 517 patients were evaluated. After the 12-weeks landmark selection, 386 (74.7%) patients were eligible for the clinical outcomes analysis. 40.4% were NSCLC, 42.2% were melanoma, 15.3% renal cell carcinoma and 2.1% other malignancies. 76 patients (19.7%) experienced early ir-fatigue (within 1 month from treatment commencement), while 150 patients (38.9%) experienced delayed ir-fatigue. Early ir-fatigue was significantly related to shortened PFS (HR = 2.29 [95% CI 1.62-3.22], p < 0.0001) and OS (HR = 2.32 [95% CI 1.59-3.38], p < 0.0001) at the multivariate analysis. On the other hand, we found a significant association between the occurrence of early ir-fatigue, ECOG-PS ≥ 2 (p < 0.0001), and disease burden (p = 0.0003). Delayed ir-fatigue was not significantly related to PFS nor OS. Early ir-fatigue seems to be negative prognostic parameter, but to proper weight its role we must to consider the predominant role of performance status, which was related to early ir-fatigue in the study population. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 17% |
| Student > Doctoral Student | 3 | 9% |
| Researcher | 3 | 9% |
| Student > Ph. D. Student | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 14 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 34% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Arts and Humanities | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 15 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2019.
All research outputs
#19,323,874
of 23,923,788 outputs
Outputs from Journal of Translational Medicine
#3,123
of 4,232 outputs
Outputs of similar age
#271,142
of 361,052 outputs
Outputs of similar age from Journal of Translational Medicine
#48
of 74 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,232 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,052 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.